orbisresearch.com added latest 139 pages report “Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017” in its store.
This report provides an overview of the toxicology pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting, Chemotherapy Induced Neutropenia, Chemotherapy Induced Anemia, Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.
Get the request a sample of ‘Global Toxicology Cluster Chemotherapy Related Toxicity Drug Market’ report
– Which companies are the most active within the pipeline for toxicology therapeutics?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in the field of toxicology therapeutics?
The size of these pipelines ranges from 16 in chemotherapy-induced anemia to 41 in chemotherapy-induced neutropenia and CIPN. In CINV and CIPN, there is a relatively diverse range of targets which are being studied, although most of these targets are neurotransmitter receptors. On the other hand, the pipelines for chemotherapy-induced neutropenia and anemia are far more limited in the range of molecular targets being studied.
These key indications are all common side effects of cancer chemotherapy treatment, and result in a substantial reduction in the patient’s quality of life. Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Chemotherapy-induced neutropenia is another very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. Chemotherapy-induced anemia symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. Finally, chemotherapy-induced peripheral neuropathy (CIPN) is a further potential side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems.
Get the discount of this report @ http://www.orbisresearch.com/contacts/discount/289234 .
Reasons to buy
– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 () 884-6817; +912064101019
Email ID: email@example.com